CoreCap Advisors LLC Acquires 3,077 Shares of Biogen Inc. $BIIB

CoreCap Advisors LLC increased its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 1,546.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,276 shares of the biotechnology company’s stock after buying an additional 3,077 shares during the period. CoreCap Advisors LLC’s holdings in Biogen were worth $577,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Empowered Funds LLC raised its stake in shares of Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after acquiring an additional 2,777 shares during the last quarter. Focus Partners Wealth grew its stake in shares of Biogen by 172.2% during the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after purchasing an additional 6,436 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Biogen in the second quarter valued at approximately $216,000. Cetera Investment Advisers increased its holdings in shares of Biogen by 2.2% in the second quarter. Cetera Investment Advisers now owns 12,888 shares of the biotechnology company’s stock valued at $1,619,000 after purchasing an additional 280 shares in the last quarter. Finally, American Century Companies Inc. raised its position in Biogen by 34.4% in the 2nd quarter. American Century Companies Inc. now owns 81,253 shares of the biotechnology company’s stock worth $10,205,000 after purchasing an additional 20,778 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: FDA approves a higher‑dose SPINRAZA regimen for spinal muscular atrophy — the approval (based on the DEVOTE study) expands an existing revenue-driving product, will be available in the U.S. in coming weeks, and is already approved in the EU, Switzerland and Japan. This is the primary catalyst lifting the stock today. Reuters: FDA approves higher-dose of Biogen’s genetic disorder drug
• Positive Sentiment: Analysts and company commentary see the high‑dose Spinraza approval as supporting Biogen’s long‑term rare‑disease franchise and revenue stability after prior regulatory delays were resolved. Proactive: High-dose Spinraza approval seen supporting long-term growth
• Positive Sentiment: Biogen reported a second positive Phase II result for litifilimab in cutaneous lupus erythematosus (CLE), adding to the pipeline narrative that could deliver new commercial opportunities if later‑stage trials succeed. The Pharma Letter: Biogen’s second positive Phase II litifilimab trial in CLE
• Neutral Sentiment: Market commentary highlights BIIB outperformed peers on a strong trading day as investors digested the Spinraza approval and clinical updates; that market reaction reflects positive sentiment but could be short‑lived if follow‑through is absent. MarketWatch: Biogen stock outperforms competitors
• Neutral Sentiment: Several analysts (Needham, Morgan Stanley and others) are maintaining Hold ratings and modest price targets — signaling that while the news is constructive, many see limited near‑term upside until commercial uptake, pricing/reimbursement and larger late‑stage data are clearer. TipRanks: Encouraging early data but competitive and clinical risks support a neutral hold
• Negative Sentiment: Analysts warn competition in lupus indications, modest Phase II effects relative to rivals, and clinical/regulatory risk could limit upside; investors should watch uptake, pricing negotiations for the new Spinraza dose, and execution on late‑stage programs. TipRanks: Balanced but constrained upside — Hold

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.18% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on BIIB. BMO Capital Markets upped their price objective on Biogen from $165.00 to $196.00 and gave the stock a “market perform” rating in a report on Friday, February 6th. Wolfe Research set a $231.00 target price on Biogen in a research note on Monday, February 9th. Mizuho boosted their target price on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Oppenheimer upped their price target on Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, January 30th. Finally, Tudor Pickering set a $201.00 price target on Biogen in a report on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $205.31.

Biogen Stock Performance

BIIB stock opened at $187.57 on Tuesday. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The company has a market cap of $27.53 billion, a P/E ratio of 21.29, a price-to-earnings-growth ratio of 1.46 and a beta of 0.15. The business’s fifty day moving average is $185.83 and its 200-day moving average is $170.70.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts forecast that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.